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Considerable research attests to the adverse effects of chronic smoking on cardiac, pulmonary,
and vascular function as well as on increased risk for various cancers. However, comparatively little is
known about the effects of chronic smoking on brain function. Although smoking rates have
decreased in the developed world (they have increased in the developing world), smoking rates have
been at a persistently high level in individuals with alcohol use disorders. Despite the high prevalence
of comorbid chronic smoking and alcohol dependence, very few studies have addressed the separate
and interactive effects that smoking and alcoholic drinking may have on neurobiology and brain
function. This symposium, which took place at the annual meeting of the Research Society on Alco-
holism in Santa Barbara, California, on June 29, 2005, postulates that the neurobiologic and neuro-
cognitive abnormalities commonly described in studies of alcohol-dependent individuals are
modulated by concurrent abuse of tobacco products and that brain recovery in abstinent alcoholic
individuals is affected by chronic smoking. Four expert speakers and a discussant from different
research disciplines focus in this symposium on the description of neurobiological and neurobehavi-
oral effects because of concomitant drinking and smoking. Understanding the potential separate
effects and interactions of chronic nicotine/smoking and alcohol consumption promotes a better un-
derstanding of specific mechanisms and neurocognitive consequences of brain injury and brain
recovery with abstinence. The material presented contributes useful information to ongoing discus-
sions about treatment strategies for these comorbid disorders and valuable educational material that
can be used to affect public perception about smoking and perhaps health policy.
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THERE WERE APPROXIMATELY 1.3 billionsmokers worldwide in 2003 (World Bank 2003) and
about 4.9 million premature deaths due to smoking-relat-
ed illnesses in 2000 (World Health Organization, WHO).
The majority of these occurred in the developed world
(North America, Europe, Australia, East Asia, and former
USSR), where death rates for tobacco use among 35- to
69-year-old males are 425%. The WHO called this sad
phenomenon rather fittingly ‘‘Dying in Your Prime.’’ We
have not, however, reached the apex of this pandemic: in
2020, there will be an estimated 10 million deaths/year
from smoking (WHO 2002: World Health Report; Peto
and Lopez, 1996), primarily because of dramatically in-
creasing smoking rates in Asia. In the United States, ap-
proximately 23% of the adult population smoke (Center
for Disease Control, CDC 2001: Report of the Surgeon
General). 440,000 Americans die from cigarette smoking
yearly (CDC: 2004: Report of the SurgeonGeneral), which
accounts for about 20% of all deaths and thereby consti-
tutes the leading cause of adult deaths.
The developed world largely recognizes the devastating
effects that chronic cigarette smoking has on pulmonary,
cardiac, and vascular function and on the dramatically
increased risks for various forms of cancer. This is in part
because of aggressive campaigns by WHO and other wide-
reaching health organizations to curb the use of tobacco
products and to raise awareness about the negative conse-
quences of chronic smoking on almost all organs and organ
systems of the human body (see e.g., The Smoker’s Body in
COLORS Magazine 1997). Over the past decades, smoking
rates within the general populations of nations across the de-
veloped world have dropped dramatically. However, smok-
ing is on the rise in developing nations and smoking rates in
the developed world remain very high among individuals
with alcohol use disorder (AUD) and other neuropsychiatric
disorders (e.g., schizophrenia, bipolar disorder).
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Approximately 50% to 80% of alcohol-dependent indi-
viduals smoke regularly, they demonstrate greater alcohol
consumption than nonsmoking alcoholic individuals
(Hurt et al., 1994; Pomerleau et al., 1997; Romberger and
Grant, 2004), and 50% to 90% (depending on the study)
of alcoholic individuals are nicotine-dependent (Room,
2004). Furthermore, most alcoholic individuals who
smoke continue to demonstrate a high level of nicotine
dependence during abstinence from alcohol (Currie et al.,
2001). Chronic cigarette smoking in alcoholic individuals
is associated with significantly higher quantity and
frequency of alcohol consumption compared with non-
smoking or former-smoking alcohol-dependent individu-
als (York and Hirsch, 1995), and animal studies showed
that nicotine increases voluntary alcohol intake (Lê et al.,
2003). Alcoholic smokers have more severe nicotine
dependence and greater difficulties quitting than nonalco-
holic smokers (Romberger and Grant, 2004). In a US
cohort treated for alcoholism, mortality associated with
cigarette smoking was 51%, whereas mortality related to
alcohol-induced diseases alone was about 34% (Hurt
et al., 1996). More than 4 times as many Americans die
from smoking-related than from alcohol-related causes
(Miller and Gold 1998; Peto and Lopez, 1996).
Despite these staggering statistics and sobering knowl-
edge about this tragic comorbidity, very little is known
about the biologic and functional consequences of chronic
smoking on brain function in AUD. Chronic, heavy alco-
hol consumption has been associated over the past 20
years with abnormalities in brain pathology and morphol-
ogy, cerebral glucose and amino acid metabolism, receptor
activity, molecular and cellular function, and neurocogni-
tion. However, to the best of our knowledge, none of these
research studies have considered chronic smoking as a
potential confound or as a factor that could possibly
explain some of the variance associated with brain injury
attributed primarily to alcoholism.
This symposium addressed the following questions:
does chronic smoking contribute to detectable brain
injury in alcoholic individuals? If so, in what way and
how much? Does chronic smoking affect recovery from
alcoholism? And if so, should this knowledge inform
current neuropharmaceutical treatments aimed at modify-
ing drinking behavior? After all, some of the same
pharmacotherapies (e.g., naltrexone) that appear to
control or modify outcomes of alcohol abuse may also
reduce smoking levels in alcoholic smokers (Rohsenow
et al., 2003). Thus, the focus of this symposium was on the
description of the neurobiological and neurobehavioral
effects of concomitant alcohol consumption and smoking.
The presenters were united in their message that under-
standing the potential separate effects and interactions of
chronic nicotine/smoking and alcohol consumption on the
brain will not only help elucidate specific mechanisms of
brain injury and recovery as well as their neurocognitive
consequences, but will also contribute useful information
to ongoing discussions about treatment strategies for these
comorbid disorders.
Various theories try to explain the high comorbidity of
smoking and alcoholic drinking. These include nicotine’s
and alcohol’s mutually potentiating rewards, nicotine
counteracting the adverse effects of alcohol on cognition
and motor incoordination (‘‘self-medication’’), and a com-
mon genetic susceptibility, with smoking possibly sharing
some of the same genetic determinants with alcoholism.
Hepatic and brain cytochrome P450 2E1 metabolism of
both alcohol and nicotine can generate reactive oxygen
species, leading to oxidative damage to cellular structures
and macromolecules including proteins, membrane lipids,
carbohydrates, and DNA (Moriarty et al., 2003) and
activation of tobacco-derived procarcinogens and nervous
tissue pathologies (Howard et al., 2003a, 2003b). Dr.
Yousef Tizabi from Howard University in Washington,
DC, in the first presentation, addressed some of these
issues by giving an overview of the basic interactions
between alcohol and nicotine. Modulation of the inhibito-
ry gamma amino butyric acid (GABA) system by alcohol
is implicated in the development of alcohol tolerance,
dependence, and withdrawal. Dr. Julie Staley from Yale
University presented recent single photon emission
computed tomography (SPECT) studies that suggest
differential regulation of cortical benzodiazepine (BZ)-
GABAA-receptors in alcoholic smokers versus nonsmok-
ers in short-term sobriety. Receptor adaptations in alcohol
dependence may contribute to the comorbidity between
alcoholism and smoking and, more importantly, suggest
that BZs commonly used to treat alcohol withdrawal
symptoms may be differentially effective in alcoholic indi-
viduals who smoke versus those who do not. Dr. Timothy
Durazzo from the DVA Medical Center San Francisco
described magnetic resonance-derived morphometric and
metabolic differences in the brains of smoking and
nonsmoking alcohol-dependent individuals during early
recovery from alcoholism and their relationships with
select neuropsychological measures. Dr. Jennifer Glass
from the University of Michigan provided a more detailed
description of the neurocognitive effects of alcoholism and
long-term smoking in a community-recruited sample of
alcoholic men and controls. Dr. SaraJo Nixon from the
University of Kentucky ended the symposium with some
closing remarks that further supported the urgent need for
more smoking-related research in alcoholism.
AN OVERVIEW OF BASIC INTERACTIONS BETWEEN
ALCOHOL AND NICOTINE
Yousef Tizabi, Vera C. Campbell, and Robert E. Taylor
Despite numerous epidemiological indications of
synergistic increases in risks of various cancers, e.g., those
of the head, neck, and esophagus as well as duodenal ulcer,
the incidence of concomitant smoking and drinking
remains high. Theoretically at least, there could be
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3 factors or mechanisms contributing to this comorbidity.
First, as alcohol and nicotine are strong reinforcers indi-
vidually, combining the 2 may yield additive or synergistic
rewarding effects (Tizabi et al., 2002). Second, pharmaco-
logical interactions between alcohol and nicotine (e.g., me-
tabolism and receptor stimulation/inhibition) could play a
significant role (Howard et al., 2003a, 2003b; Narahashi
et al., 2001). Finally, there may be genetic factors contrib-
uting to concomitant addiction to alcohol and nicotine.
Indeed, various studies are suggestive of the existence of
common genes that can make an individual susceptible to
becoming dependent on both alcohol and nicotine (Li
et al., 2005; Madden and Heath, 2002).
Support for possible additive rewarding effects of alco-
hol and nicotine is provided by studies demonstrating
activation of mesolimbic dopamine pathway by each drug
individually and in combination. Activation of the
mesolimbic system, reflected in dopamine release from the
nucleus accumbens, is believed to be intimately involved in
reinforcing effects of drugs (see Pierce and Kumaresan,
2005, for a recent review). We have observed the additive
effects of alcohol and nicotine on dopamine release from
the nucleus accumbens shell (NACC). Thus, submaximal
doses of systemic alcohol, when combined with submaxi-
mal doses of nicotine injected directly into the ventral teg-
mental area (VTA), resulted in additive release of
dopamine in NACC (Tizabi et al., 2002). This effect was
also seen when combining systemic alcohol with systemic
nicotine (Tizabi et al., 2004a). Moreover, the stimulatory
effects of alcohol on dopamine release was blocked by
injection or infusion of the nicotinic receptor antagonist
mecamylamine into the VTA, suggesting that at least some
of the reinforcing effects of alcohol may be mediated
through its interactions with the nicotinic receptors in
VTA (Ericson et al., 1998; Tizabi et al., 2002). This con-
tention is further supported by studies demonstrating a
suppressive effect of mecamylamine on alcohol intake in
rats (Ericson et al., 1998; Larsson and Engel, 2004; Lê
et al., 2000). Several human studies have also provided
evidence for mecamylamine-induced attenuation of the
euphoric or stimulant effects of alcohol as well as a
decrease in the desire to consume more alcohol (Blomq-
vist et al., 2002; Young et al., 2005).
The reinforcing effects of a drug of abuse may be
enhanced if the drug, in addition to a euphoric effect, also
possesses an analgesic or antinociceptive effect. In this
regard, both alcohol and nicotine have been shown to
have analgesic properties. An additive or synergistic
antinociceptive effect of alcohol and nicotine may further
contribute to their coabuse. Recently, we have observed a
supraadditive antinociceptive effect of alcohol and
nicotine combination. This effect was manifested in both
spinal- and supraspinal-mediated analgesia where ineffec-
tive doses of alcohol and nicotine, when combined, result-
ed in antinociception. Thus, in both tail flick (spinally
mediated nociception) and hot plate (supraspinally
mediated nociception) tests, acute administration of lower
doses of alcohol and nicotine, which had no anti-
nociceptive effects alone, when combined resulted in sig-
nificant antinociception (Campbell et al., 2005). These
preliminary findings indicate that the combined reinforc-
ing effects of alcohol and nicotine may be a contributory
factor to their coabuse.
It is now well documented that neuronal nicotinic recep-
tors (nAChRs) are targeted by alcohol andmanipulations of
these receptors can modify the behavioral as well as the
neurotoxicological effects of alcohol (Larsson and Engel
2004; Narahashi et al., 2001; Tizabi et al, 2003, 2004b).
These receptors are ligand-gated ion channels and are
believed to be involved not only in drug dependency but al-
so in diverse functions such as cognitive functions including
attentional processes, learning and memory, and synaptic
plasticity and neuroprotection. Various nAChR subtypes
with distinct distribution and function have been identified.
These receptors are composed of pentamer subunits, which
can combine to form heteromeric (e.g., a4-b2, a3-b2, a6)
or homomeric (e.g., a7) subtypes. Of these, the high-affinity
nicotinic receptor (a4-b2) or the low-affinity subtype (a7) are
most abundant and widely distributed in the brain. Recent
data indicate that the subunit containing a3 or a6 may be
most directly involved in alcohol activation of the me-
solimbic dopamine pathway (Larsson et al., 2004).
In addition to in vivo interactions between alcohol and
nicotinic receptors described above, in vitro interactions
have also been amply documented. Thus, it has been dem-
onstrated that ethanol stabilizes the open channel state of
the nicotinic receptors and that fast nicotinic receptor
desensitization is enhanced by ethanol (Wu and Miller
1994). Moreover, nAChR subtypes may be differentially
modulated by ethanol (Gorbounova et al 1998). Electro-
physiological studies in cultured cortical neurons suggest
that nicotinic receptors are sensitive conduits for
mediating the central actions of ethanol and that ethanol
may increase nAChR affinity for its endogenous ligand,
acetylcholine (Narahashi et al., 1999). In parallel with
these in vitro studies, it has been reported that long-term
ethanol treatment may affect nicotinic receptor densities in
selective brain regions of rats and mice (Booker and
Collins, 1997; Yoshida et al., 1982). We have also report-
ed that inherent preference for alcohol may be influenced
by differential expression of striatal nicotinic receptors
(Tizabi et al., 2001). Moreover, in drug discrimination
paradigms, nicotine may substitute for ethanol in alcohol-
preferring rats (Mcmillan et al., 1999).
Pharmacological interactions between alcohol and nico-
tine are further manifested in cross-tolerance observations
as well as metabolic influences (Collins et al., 1996;
Howard et al., 2003a, 2003b). As stated above, counterac-
tion of the adverse effects of 1 drug by another could be a
strong factor in combining the 2 drugs together. In this
regard, alcohol-induced motor incoordination may be
overcome by central administration of nicotine (Dar
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et al., 1994). Alcohol may also interact with nicotinic
receptors to induce cognitive impairments. Nicotine, con-
versely, may overcome the adverse effects of alcohol via
selective activation of nicotinic receptors (Wehner et al.,
2004). We have observed that alcohol-induced toxicity in
primary cortical and cerebellar granule cells may be
blocked by nicotine pretreatment, suggesting a neuropro-
tective role for nicotine (Tizabi et al., 2003, 2004b). Inter-
estingly, both high-affinity and low-affinity nicotinic
receptors appear to be involved in this effect of nicotine.
Blockade or attenuation of ethanol effects by nicotine or
nicotinic agonists is also evident in several other in vitro
studies using hippocampal slices or neuron-like
pheochromocytoma (PC12) (Li et al., 2002; Prendergast
et al., 2000). Considerable research has been dedicated to
elucidation of the central site of nicotine effect as well as
the specific nicotinic receptor subtype mediating the effect
of nicotine with the expectation that such information
would result in novel pharmacotherapies for drug addic-
tion and/or neuropsychiatric or neurological disorders.
It is very important to note that the effects of smoking
have to be distinguished from the effects of nicotine alone.
Hence, whereas nicotine may act as a neuroprotective
agent, other compounds in cigarette smoke may have quite
the opposite effect. It is also conceivable that under
specific conditions, nicotine may exacerbate or exaggerate
some of the adverse effects of alcohol. Thus, the higher in-
cidence of cancers in individuals with a history of heavy
drinking and smoking may be aided by nicotine’s ability to
bioactivate tobacco-derived procarcinogens. This conten-
tion is based on the observation that cytochrome P450
2E1, which can activate procarcinogens, can be induced by
both alcohol and nicotine (Howard et al., 2003a, 2003b).
In summary, genetic factors and pharmacological inter-
actions between alcohol and nicotine may be critical
determining factors in comorbid conditions of drinking
and smoking. Further elucidation of the neurobiological
substrates of these interactions could lead to novel inter-
ventions in alcoholism, smoking, or their combination.
Acknowledgments. NIH P20 AA014643, NIH 2SO6
GM08016-33.
CORTICAL BENZODIAZEPINE RECEPTORS IN
ALCOHOL-DEPENDENT SMOKERS VERSUS
NONSMOKERS IN SHORT-TERM SOBRIETY
Julie K. Staley, Graeme Mason, Ismene Petrakis, and
John H. Krystal
Smoking and alcoholism are synergistically associated in
the general population such that persons who drink and
smoke drink more than nonsmokers and drinkers smoke
more than nondrinkers (Abrams et al., 1992; Bien and
Burge, 1990; DiFranza and Guerrera, 1990; Gulliver et al.,
1995; Johnson and Jennison, 1992). Alcohol-dependent
smokers have an earlier age of onset of alcohol dependence
and more alcohol-related problems (Deappen et al., 2000).
Importantly, smokers feel less intoxicated upon alcohol
challenge, suggesting that smoking enhances tolerance to
alcohol (Madden et al., 1995). While a central role for aber-
rant GABAergic function in alcohol dependence has been
appreciated for decades, the role of GABA systems in ciga-
rette smoking has been poorly studied. The paucity of stud-
ies on the regulation of GABA systems by tobacco smoke is
shocking, given the high rate of comorbidity between alco-
holism and tobacco smoking. Alcohol, like BZs, the primary
treatment for alcohol withdrawal symptoms, facilitates
GABA function. In contrast, cigarette smoke contains b
carbolines that block the actions of BZ at GABAA recep-
tors, suggesting that tobacco smoking opposes the effects of
alcohol at the GABA receptor and facilitates tolerance to
the effects of alcohol. Initial studies in alcohol-dependent
individuals abstinent for 34  20 days demonstrated that
GABA levels were decreased in the occipital cortex (Behar
et al., 1999). Preliminary evidence of low cortical GABA
levels in localized 1H-MR spectra of alcohol-dependent and
hepatic encephalopathy patients and in alcohol-dependent
participants abstinent for 1 to 6 months shows that BZ-
GABAA receptor availability was decreased in the frontal,
anterior cingulate, occipital, and cerebellar cortices (Abi-
Dargham et al., 1998) compared with healthy participants.
These preliminary findings suggest that cortical GABA
function is decreased over extended abstinence.
In the present studies, we sought to determine whether
these GABAergic deficits also marked the early stages of
recovery from alcohol dependence or whether they were
solely expressed after an extended period of abstinence and
whether smoking influenced the adaptive changes in
GABAA-receptor and GABA levels and the severity of
alcohol withdrawal during early sobriety. Specifically, alco-
hol-dependent participants who entered the study became
inpatients for 1 month. During this time, they participated
in 2 [123I]iomazenil SPECT scans to measure BZ-GABAA
receptor levels and 2 magnetic resonance imaging (MRI)
scans, performed during the first week of abstinence (o7
days) and repeated at 4 weeks of abstinence. To assess the
effects of smoking, alcohol-dependent participants were
classified by smoking status so that ato7 days abstinence,
we studied 8 alcohol-dependent nonsmokers (39.9  8.6
years) and 15 alcohol-dependent smokers (40.6  8.1
years), and at 1 month of sobriety we studied 6
alcohol-dependent nonsmokers (40.8  9.9 years) and 14
alcohol-dependent smokers (38.4  7.0 years). These 4
groups of alcohol-dependent participants were compared
with a single group of 15 control participants who included
10 nonsmokers (35.9 7.5) and 5 smokers (41.2 9.2)
(Staley et al., 2005). Alcohol-dependent smokers and non-
smokers were similar in most clinical variables of alcohol
drinking including age of onset, family history of smoking,
severity of alcohol dependence as determined by the Alco-
hol Dependence Scale, and severity of craving for alcohol as
measured using the Tiffany Scale for Alcohol Craving.
Although the repeated time-line followback suggested that
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alcohol-dependent smokers tended to have drunk more alco-
hol units in the past month (490.7 170.4 and 444.3 194.6
ato7 days and 4 weeks withdrawal, respectively) compared
with alcohol-dependent nonsmokers (340.6 148.7 and
381.2 135.6 at o7 days and 4 weeks withdrawal, respec-
tively), the differences were not statistically significant.
Comparisons of cortical [123I]iomazenil uptake (deter-
mined by the outcome measure VT [regional activity/free
plasma parent], which correspond to the binding potential
or [Bmax/KD]) between these 5 groups (Fig. 1), suggested
that GABAA-BZ receptors were higher in the frontal cortex
(Brodmann’s area 47), parietal cortex (Brodman’s area 40),
insular cortex (Brodmann’s area 13), temporal cortex
(Brodmann’s area 21), and occipital cortex (Brodmann’s
area 17, 19) of alcohol-dependent nonsmokers imaged with-
in 4.6  1.8 days from their last alcohol drink, compared
with controls (po0.05 corrected for multiple comparisons).
Alcohol-dependent smokers imaged within 5.0  2.9 days
were not different from controls. After 4 weeks of sobriety
from alcohol, cortical [123I]iomazenil uptake was not signif-
icantly altered in alcohol-dependent nonsmokers or
smokers compared with controls, suggesting that the GA-
BAA-BZ receptor normalizes over the first month of
abstinence from alcohol in alcohol-dependent nonsmokers.
[123I]Iomazenil uptake during the first week of sobriety
correlated positively with the days since last drink in alco-
hol-dependent nonsmokers, suggesting that the higher
iomazenil uptake reflected a compensatory increase in
GABAA-BZ receptors during acute alcohol withdrawal.
The lack of higher iomazenil uptake combined with the
lack of a correlation between iomazenil uptake and days
since last alcohol drink in alcohol-dependent smokers sug-
gests that smoking suppressed the compensatory adaptive
increase in GABAA-BZ receptors during acute alcohol
withdrawal. Iomazenil uptake in the occipital cortex (Brod-
mann areas 17, 18, and 19) and the cerebellum at o7 days
of abstinence correlated with the severity of alcohol with-
drawal (p5 0.01 corrected for multiple comparisons) in
the combined group of alcohol-dependent smokers and
nonsmokers. This suggests that GABAA-BZ receptor avail-
ability may predict the severity of alcohol withdrawal.
Given that in this sample, the alcohol-dependent nonsmok-
ers tended to demonstrate more severe alcohol withdrawal
(peak CIWA scores of 6.9 4.8; mean  SD) compared
with alcohol-dependent smokers (peak CIWA 4.5  2.9
mean SD), these findings imply that by suppressing the
compensatory increase in GABAA-BZ receptors, smoking
may suppress alcohol withdrawal symptoms.
In an overlapping sample of participants, occipital
GABA levels were measured using magnetic resonance
spectroscopy (MRS). This study population included 12
alcohol-dependent individuals (5 nonsmokers and 7
smokers) and 8 control individuals (4 nonsmokers and 4
smokers) (Mason et al., 2005). A tendency toward higher
cortical GABA levels was noted in alcohol-dependent non-
smokers at 5 days of abstinence compared with control
individuals (p5 0.09), and cortical GABA levels were sig-
nificantly higher in alcohol-dependent nonsmokers com-
pared with alcohol-dependent smokers at 5 days of
sobriety (p5 0.004). At 4 weeks of sobriety, GABA levels
in nonsmokers had normalized to the same level as in
alcohol-dependent smokers and they were not significantly
different from levels in control.
Collectively, the findings suggest that the severity of






























0 10 20 30
scan number
40 50 60
Fig. 1. [123I]Iomazenil binding to brain GABAA-BZ receptors in alcoholic
smokers and nonsmokers. Top: Brain areas that are significantly different
(F5, 53 4300) for comparisons of [
123I]iomazenil uptake (VT) between 5
groups including: Group 1, healthy controls (n 5 15); Group 2, alcohol-
dependent smokerso1 week abstinence (n 5 15); Group 3, alcohol-dependent
nonsmokerso1 week abstinence (n 5 8); Group 4, alcohol-dependent smokers
4 weeks abstinence (n 5 14); Group 5, alcohol-dependent nonsmokers 4
weeks abstinence (n 5 6) . Bottom: Plot of the activity at the voxel with the
highest F value in (A). Dots represent actual VT values for individual partici-
pants in each group; the mean values for each of the 5 groups are represented
by the line. These findings suggests that the alcohol-dependent nonsmokers
(ANSo1 week) have higher uptake at 1 week of abstinence compared with
controls and alcohol-dependent smokers (aS o1 week and AS4 weeks). BZ,
benzodiazepine, GABA, g-aminobutyric acid.
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receptor availability and that withdrawal severity is sup-
pressed by cigarette smoking. Furthermore, these data
demonstrate time-dependent regulation of cortical GABA
and GABAA-BZ receptors associated with the recovery
from alcohol dependence. Higher GABAA-BZ receptor
levels may reflect subunit changes and decreased GABAA-
BZ receptor function induced by protracted alcohol
drinking. Higher GABA levels during acute withdrawal
may reflect a compensation for reduced receptor function,
thought to contribute to alcohol tolerance and with-
drawal, whereas the subsequent decline may reflect ‘‘nor-
malization’’ of GABAA receptor function with sobriety.
Smoking may attenuate GABAA receptor adaptations
associated with alcohol dependence and may contribute to
the comorbidity between alcoholism and smoking. Given
that BZs are usually the first line of treatment for alcohol
withdrawal symptoms, these findings suggest that BZs
may be differentially effective in alcohol-dependent indi-
viduals who smoke versus those who do not.
Acknowledgments. NIH K01AA00288, NIH K05
AA014715-01, NIH RO1 AA1132, NIH P50 DA13334;
the Dana Foundation; the Mental Illness Research, Edu-
cation, and Clinical Center for Dual Diagnosis (MIRE-
CC); and the VA Alcohol Research Center.
BRAIN STRUCTURE, METABOLITES, AND PERFUSION
IN ALCOHOLIC SMOKERS AND NONSMOKERS DURING
SOBRIETY
Timothy C. Durazzo, Stefan Gazdzinski, Peter Banys, and
Dieter J. Meyerhoff
Tobacco products (mainly cigarettes) are the most com-
monly used substances among actively drinking and
recovering alcoholic patients. Increasing evidence from
neuroimaging studies links chronic smoking to adverse
effects on brain morphology, cerebral blood flow, and
neurochemistry independent of excessive alcohol con-
sumption. Compared with nonsmokers, chronic smokers
demonstrated lower cortical gray matter volumes and
densities in the prefrontal cortex, smaller left anterior
cingulate volume, and lower gray matter densities in the
right cerebellum (Brody et al., 2004), as well as increased
generalized brain atrophy with advancing age (Hayee et
al., 2003). Active smokers showed lower global cerebral
blood flow and limbic system blood flow (Domino et al.,
2004) than nonsmokers. It appears that chronic cigarette
smoking has some of the same adverse effects on the hu-
man brain as chronic alcoholism; however, the potential
neurobiologic consequences of chronic cigarette smoking
were not considered in past neuroimaging studies of indi-
viduals with AUD. Thus, it is unclear whether the full
extent of the neurobiological abnormalities reported in
neuroimaging studies with alcoholic individuals are solely
related to chronic, excessive alcohol consumption or
whether concurrent chronic cigarette smoking may con-
tribute to the aberrations observed.
In 1-week abstinent recovering alcoholic patients (RA),
we investigated brain morphology with high-resolution
MRI (Gazdzinski et al., 2005), brain metabolite concent-
rations with proton magnetic resonance spectroscopic
imaging (1H MRSI) (Durazzo et al., 2004), and brain per-
fusion with pulsed arterial spin labeling. RA were again
studied with 1H MRSI after 1 month of abstinence. To
investigate the potential independent and combined effects
of concurrent chronic cigarette smoking and alcohol
dependence, we retrospectively divided our RA cohort
into smokers and nonsmokers. All data were acquired on
a clinical 1.5-T MR scanner.
Cross-sectional MR Studies in 1-week Abstinent Recovering
Alcoholic Patients
High-resolution 3-dimensional MRIs were acquired
from 1-week abstinent nonsmoking RA (nsRA; n5 13;
age 49.8  9.7 years) and smoking recovering alcoholic
patients (sRA; n5 24; age 49.4  8.3 years) as well as
from light drinking (LD) nonsmokers (nsLD; n5 7; age
47.5  6.0 years) and smokers (sLD; n5 23; age
38.1  8.7 years). All RA met Diagnostic and Statistical
Manual-fourth edition (DSM-IV) criteria for alcohol de-
pendence with physiological dependence. Smoking recov-
ering alcoholic individuals consumed 290  120, and
nsRA 200  120 drinks per month over a lifetime. Smok-
ing recovering alcoholic individuals smoked 21  8 ciga-
rettes per day for 23  13 years; cigarette pack–years was
26  19 and their Fagerstrom score was 5.5  1.9. Eighty-
seven percent of sLD participants smoked daily or nearly
every day. A brief neurocognitive battery assessed visuo-
spatial learning and memory, working memory, and vis-
uomotor scanning and incidental learning. Regional white
matter (WM), gray matter (GM), and CSF volumetry,
corrected for intracranial volume, used automated pro-
babilistic segmentation, combined with automated atlas-
based region labeling of the major lobes, cerebellum, and
subcortical structures (Fig. 2). Regional brain volumes
were converted into age-corrected z scores based on nsLD.
Multivariate analysis of variance for all measured regions
yielded main effects for both alcohol and smoking. Fol-
low-up ANOVAs demonstrated alcohol main effects for
the parietal and temporal GM, with less GM in RA than
LD. Significant smoking effects were found for parietal,
temporal, and occipital GM, where smokers demonstrated
less GM in these regions than nonsmokers (Fig. 3). Alco-
hol main effects were also seen for the frontal WM and
parietal WM, with smaller WM in RA compared with LD.
A large smoking main effect for the temporal WM and a
trend for frontal WM were observed, with larger WM
volumes in smokers versus nonsmokers. In nsRA, visuo-
spatial learning and memory positively correlated with
temporal WM and occipital WM volumes. No significant
structure–neurocognitive relationships were noted for
sRA. The larger temporal and frontal WM volumes in
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sRA may be associated with cytotoxic and/or vasogenic
swelling secondary to smoking-induced alterations in
mitochondrial function and vascular endothelial damage,
respectively. It has been suggested that late-myelinating
areas such as the frontal and temporal lobes may be par-
ticularly vulnerable to increased oxidative stress and cere-
bral hypoperfusion (see Bartzokis, 2004a, 2004b), which
are both found in chronic smokers. In general, findings of
GM loss are functionally significant, as brain shrinkage is
a risk factor for cognitive decline and memory impairment
in the elderly.
Short-echo-time multislice 1H MRSI was performed
on 14 nsRA and 10 sRA. RA participant demographics,
smoking characteristics, and neurocognitive measures
administered were similar to those reported for the brain
morphology study. Concentrations of N-acetylaspartate
(NAA), choline-containing compounds (Cho), and other
metabolites were derived from spectra (see Fig. 2 for an
example spectrum) measured in 3 parallel planes through
the centrum semiovale, basal ganglia, and cerebellar vermis.
Regional atrophy-corrected metabolite concentrations were
calculated by combining 1H MRSI and segmented MRI
data. Smoking recovering alcoholic individuals compared
with nsRA demonstrated 10% lower NAA in the frontal
WM and 15% lower NAA and 21% lower Cho in the mid-
brain (Fig. 4). In addition, sRA showed trends to lower
NAA in the parietal GM and lenticular nuclei. Results were
unchanged after controlling for nonsignificantly higher
average number of drinks per month over a lifetime in
sRA. In sRA, higher nicotine dependence and number of
cigarettes smoked per day were negatively correlated with
thalamic and lenticular NAA levels. In nsRA, cerebellar
vermis NAA was positively related to visuospatial learning
and visuospatial memory, whereas in sRA, cerebellar
vermis NAA was positively related to visuomotor scanning
speed and incidental learning. Lower brain metabolite
levels in sRA may be related to the additional direct and
indirect biologic consequences associated with chronic
cigarette smoking such as decreased cerebral perfusion,
hypoxia, and increased oxidative stress.
Perfusion-weighted images (PWI) were acquired with a
new pulsed arterial spin labeling method (Jahng et al., 2003)
from 36 one-week abstinent RA (10 nsRA and 19 sRA) and
19 nsLD (Gazdzinski et al., 2006). Demographics and
smoking characteristics were similar to those reported for
the brain morphology study. Multivariate analysis of vari-
ance on frontal and parietal GM perfusion for all 3 groups
demonstrated a group effect where sRA showed lower fron-
tal GM perfusion (Fig. 5) and parietal GM perfusion than
both nsLD and nsRA. Gray matter perfusion was similar in
nsRA and nsLD. Parietal GM perfusion in sRA correlated
inversely with the number of cigarettes smoked per day, but
it did not correlate with recency of last cigarette smoked.
This suggests that chronic and not acute effects of cigarette
smoking modulate brain perfusion in RA.
Longitudinal 1H MRSI Studies over 1 Month of Abstinence
from Alcohol
Short-echo time multislice 1H MRSI was performed
with 11 nsRA and 14 sRA 6  3 days after consumption
Fig. 2. Left: Top images—identification of major anatomical subdivisions using atlas-based methods; bottom images—probabilistic segmentation of high-
resolution T1-weighted magnetic resonance images. The images show probabilities for cerebrospinal fluid, gray matter, and white matter, where higher prob-
abilities of correct tissue classification are reflected in brighter color. Right: Example of a single metabolite spectrum obtained from 1 of the 3 spectroscopic
imaging planes. The orange line represents the experimental spectrum and the green line shows the fitted spectrum. mI, myoinositol; Cho, choline-containing






























Fig. 3. Comparison of parietal and occipital gray matter volumes among
1-week abstinent smoking recovering alcoholic individuals (sRA) and non-
smoking recovering alcoholic individuals (nsRA). Larger negative z scores
reflect greater volume loss relative to nonsmoking light drinkers (mean and SE).
i.u., institutional units.
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of their last alcoholic drink and again after 34  10 days of
abstinence. Demographics and smoking characteristics
were similar to those reported for the brain morphology
study. The nsRA group showed an increase of frontal WM
NAA and a trend toward increasing frontal GM NAA
over 1 month of abstinence. Nonsmoking recovering alco-
holic individuals demonstrated significant Cho increases
in the GM of the frontal, parietal, and temporal lobes, as
well as Cho increases in the WM of the frontal, parietal,
temporal, and occipital lobes. In the sRA group, NAA
concentrations significantly increased only in the frontal
GM, while NAA decreased in both the parietal WM and
the occipital WM over 1 month of abstinence from alco-
hol. Smoking recovering alcoholic individuals demon-
strated Cho increases only in the frontal lobe. The localized
and rather poor recovery of Cho in the sRA cohort during
short-term abstinence from alcohol may be related to con-
tinued exposure to the numerous sources of oxidative stress
in cigarette smoke.
These preliminary MR studies in abstinent RA suggest
the following: (1) chronic alcohol dependence and ciga-
rette smoking both promote volume loss in cortical GM,
and smoking is associated with (pathological?) increases in
temporal WM volume; (2) cigarette smoking compounds
1H MRSI are markers of chronic alcohol-induced neu-
ronal injury and cell membrane damage in the frontal
lobes and the midbrain of 1-week abstinent RA in a dose-
dependent manner; (3) chronic cigarette smoking com-
pounds alcohol-induced perfusion deficits in the frontal
and parietal GM of 1-week abstinent RA; (4) chronic cig-
arette smoking adversely affects brain metabolite recovery
during short-term abstinence from alcohol (up to
1 month); and (5) chronic smoking in RA may further
compromise alcohol-induced disturbances in functional
neurocircuitry (Sullivan and Pfefferbaum, 2005) thereby
modulating relationships between MR-derived neurobiol-
ogic measures and neurocognition; therefore, examining
RA as a single group irrespective of smoking status may
obscure the ability of MR-derived neurobiologic measures
to serve as useful surrogate markers of brain function.
Overall, our preliminary results suggest that the effects
of concurrent chronic cigarette smoking should be con-
sidered in future studies investigating the consequences of
AUD on brain structure, function, metabolism, and their
recovery during abstinence, as well as in research of other
neuropsychiatric conditions (e.g., bipolar disorder, schiz-
ophrenia) in which cigarette smoking is highly comorbid.
Acknowledgment. NIH R01 AA10788 (Meyerhoff)
NEUROCOGNITIVE FUNCTION, SMOKING, AND
ALCOHOLISM
Jennifer M. Glass, Kenneth M. Adams, Joel T. Nigg, Maria
M. Wong, Leon I. Puttler, Anne Buu, Jennifer M. Jester,
Hiram E. Fitzgerald, and Robert A. Zucker
A substantial literature documents neurocognitive defi-
cits in severe, chronic alcoholic men (Knight and Long-
more, 1994). The observed impairments include difficulties
with visual–spatial processing, problem solving, memory,
and cognitive proficiency (Nixon et al., 1995, 1998) .Var-
iability across studies in both the magnitude and the type

















































Fig. 4. Comparison of frontal N-acetylaspartate (NAA) (left) and midbrain Cho concentrations (right) among 1-week abstinent smoking recovering alcoholic























P= .001 P= .003
Fig. 5. Comparison of frontal gray matter perfusion among nonsmoking
light drinkers and 1-week abstinent smoking recovering alcoholic individuals
(sRA) and nonsmoking recovering alcoholic individuals (nsRA). Higher values
represent greater perfusion (mean and SE). i.u., institutional units.
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of neurocognitive deficits observed points to multiple
paths to brain and cognitive dysfunction among alcoholic
individuals (Adams and Grant, 1986; Tarter and Edwards,
1986), including comorbid psychological and medical con-
ditions secondary to alcoholism. Additionally, abuse of
other drugs is common among alcoholic populations and
is a factor that is addressed by researchers as it is expected
to affect neurocognitive function (Nixon et al., 1998).
However, one important and commonly used other drug
that has received little attention on neurocognitive func-
tion in alcoholism is nicotine/cigarette smoking. Estimates
of cigarette smoking among alcoholic individuals range
from 50% to 80%, compared with 23% in the general
population in the United States (see Introduction); yet it is
generally not mentioned in studies of neurocognitive
function in alcoholism. This is a potentially important
gap in understanding, because chronic cigarette smoking is
linked to poor cognitive performance.
Cigarette smoking has 2 potentially different effects on
neurocognitive performance, an acute effect of nicotine
and a chronic effect because of long-term smoking (e.g.,
vascular disease and chronic obstructive pulmonary dis-
ease). Acute administration of nicotine leads to some
improvement in cognitive performance, especially on tasks
of sustained attention or vigilance (Ernst et al., 2001). This
has even been demonstrated in alcoholic patients (Crad-
dock et al., 2003). Conversely, chronic cigarette smoking is
associated with cognitive impairment in several epidemio-
logical studies. For example, smokers performed more
poorly than both never-smokers and ex-smokers on tests
of general cognitive function (Galanis et al., 2000), work-
ing memory (Ernst et al., 2001), psychomotor speed
(Hill, 1989; Kalmijn et al., 2002), and cognitive flexibility
(Kalmijn et al., 2002). In sum, although there are beneficial
effects from nicotine on cognitive performance, the long-
term effects of smoking are clearly negative and seem most
pronounced on measures that emphasize the ability to rap-
idly and flexibly process information.
We hypothesized that smoking may be an important
part of the etiology of neurocognitive impairment in alco-
holic individuals. Because smoking is more prevalent
among alcoholic individuals, previous studies may have
been biased and differences in neurocognitive function
may have been attributed to alcoholism that were in fact
associated with the different rates of smoking in the alco-
holic and control groups.
We examined this hypothesis (Glass et al., 2005) in a
community-recruited sample (n5 172) of alcoholic men
and controls who were taking part in a longitudinal family
study of risk factors for substance abuse in children
(Zucker et al., 1996). Neurocognitive function was meas-
ured with intelligence quotient (IQ) from the short version
of the Wechsler Adult Intelligence Scale-Revised (Sattler,
2001) and cognitive proficiency from the Microcog Assess-
ment of Cognitive Functioning (Powell et al., 1994).
Microcog assesses 6 distinct aspects of cognitive function
(short-term memory, immediate recall, delayed recall,
visual–spatial ability, verbal reasoning, and mathematical
reasoning) and provides a measure of global cognitive
proficiency (accuracy scaled by response time) as well as
proficiency for each subtest. Proficiency has been shown to
be a more sensitive measure of neurocognitive function in
alcoholic individuals than accuracy alone (Nixon et al.,
1995, 1998) and information processing fluency or profi-
ciency impairments are reported for smokers; therefore,
we focused our analyses on the global proficiency measure
provided by Microcog and on IQ.
Alcoholism was measured in several ways as follows:
lifetime DSM-IV diagnosis, long-term average rate of
drinking (past 9–12 years), short-term average rate of
drinking (past 6 months), and with the Lifetime Alcohol
Problems Score (LAPS). We found that LAPS was most
highly and consistently correlated with the neurocognitive
measures, so it became the measure of alcoholism used in
subsequent analyses. LAPS is constructed of 3 subscores
that assess onset, variety, and life-invasiveness of alcoholic
symptoms. Smoking was measured by pack-years (average
cigarette smoking measured in packs per day multiplied by
years of smoking).
Both smoking and alcoholism were correlated with
worse neurocognitive function; when both were included
in regression analyses, smoking remained a significant pre-
dictor of both IQ and cognitive proficiency, but alcoholism
was significant only for IQ (Figs. 6 and 7). This suggests
that smoking mediated the effect of alcoholism for the
proficiency measure, but both smoking and alcoholism are
unique predictors of IQ. The interaction between smoking
and alcoholism was not significant for either IQ or cogni-
tive proficiency.
We also examined the effects of smoking and alcoholism
on response inhibition using the stopping task that meas-
ures the ability to withhold a response during a reaction-
time task. In 25% of trials, a tone is presented that signals
the participants to stop or withhold their response. The
timing of the tone is dynamically adjusted so that each
participant’s ability to stop a response can be measured
(the Stop RT; Logan et al., 1984). A slow Stop RT is
associated with impulsiveness and poor response inhibi-
tion (Nigg, 1999). Again, both smoking and alcoholism
were correlated with slower Stop RTs. When included in a
regression analysis, both smoking and alcoholism and the
interaction were significant predictors of Stop RT (Fig. 8).
This suggests that smoking and alcoholism are uniquely
associated with the ability to stop a response and that
smoking and alcoholism combine to predict even worse
performance on the stopping task.
These results demonstrate that smoking is an important
factor to consider when studying cognitive function in an
alcoholic sample. It appears that for measures of fast,
flexible performance, smoking may explain the effects of
alcoholism, but for other measures such as IQ or response
inhibition, both smoking and alcoholism are predictors of
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neurocognitive function. It is tempting to speculate that
long-term effects of nicotine on brain function, or long-term
effects of smoking on cerebro-vascular health may explain
these results. Further study will be necessary to establish a
causal mechanism and to generalize the findings to women.
Acknowledgments. NIH R337 AA07065 and NIH
AA12217 (Zucker, Fitzgerald, Nigg)
DISCUSSION
SaraJo Nixon
The direct and interactive effects of nicotine on brain
function have been clinically and anecdotally appreciated
for some time. However, the systematic study of acute and
chronic nicotine use, particularly in individuals with other
substance use disorders, has received little general atten-
tion. Over the past decade, though, some concerted efforts
have been directed toward addressing this paucity of
research in both basic and applied applications. This sym-
posium presented research overviews and cutting-edge
science that suggests that the neurobiologic and neurocog-
nitive abnormalities commonly described in past studies of
alcohol-dependent individuals may be at least partially
modulated by concurrent chronic tobacco use. Further-
more, behavioral recovery, if not biological brain recovery
in abstinent alcoholic individuals may be affected by
chronic and continued smoking. This latter issue is only
beginning to be addressed in dose-response studies of
acute nicotine administration in otherwise abstinent sub-
stance abusers. Initial data suggest that nicotine may be
differentially effective in altering attentional processes
(e.g., vigilance and covert visual attention), with abstinent
alcoholic individuals being more sensitive to nicotine’s
cognitive-enhancing effects than other substance abuse
groups, such as stimulant abusers without a history of
alcohol dependence (Fig. 9) (Ceballos et al., 2006).
This symposium was intended to raise awareness among
fellow researchers that smoking can no longer be ignored
as a potentially significant contributor to brain injury in
alcoholism. Current research methodology is able to con-
tribute to our understanding of the potential separate and
interactive effects of chronic nicotine/smoking and alcohol
consumption at the molecular, biological, and cognitive/
behavioral levels. Specific mechanisms of biological brain
injury and recovery from alcoholism can be illuminated in
humans as a function of smoking status and in connection
with common and distinctly separate neurocognitive con-
sequences of smoking. Nevertheless and despite the well-
known comorbidity, this type of research has not received
sufficient attention in the past. The organizers and pre-
senters of this symposium expect that they contributed
useful information to both smoking and alcohol research
that ultimately can inform ongoing discussions about
treatment strategies for these often comorbid disorders,
educate the public, and possibly influence health and pub-
lic policy in general.
ACKNOWLEDGMENTS
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Fig. 7. Cognitive proficiency, smoking, and alcoholism.






























* transformed data; p=.02 vs. controls
*
Fig. 9. Higher nicotine levels improve vigilance in alcoholic individuals
(alcs). alc-stims, stimulant abusers with a history of alcohol dependence;
stims, stimulant abusers without a history of alcohol dependence.
Fig. 6. Intelligence quotient, smoking, and alcoholism.
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Natalie Ceballos, Andrea Craddock, Robert Prather, Am-
anda Ross.
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